Shredded documents and trick cameras: FDA knocks Indian drugmaker Windlas for brazen errors

Shredded documents 2019
Windlas employees allegedly spirited away "cartloads" of shredded documents while FDA investigators were on-site in May. (Pixabay)

When the FDA comes down on drug manufacturers, it can be for a range of wrongdoings, including poor testing policies and unsanitary conditions. But shredding key documents and leading investigators to incorrect rooms during an inspection? That's bold, and Indian drugmaker Windlas could pay the price.

The FDA said Windlas Healthcare failed to adequately address a slew of issues at its Dehradun, India, plant including employees shredding and disposing of key documents and clandestinely signing paperwork while investigators were on-site, according to a warning letter (PDF) published Tuesday. 

Among the most egregious errors found during a May inspection were employees moving "cartloads of trash bags" with shredded documents off-site within minutes of investigators arriving, the FDA said. In the bags were shredded batch reconciliation forms, cleaning and dispensing logs, training assessments and scale balance printouts, investigators said. 

Later during the inspection, an investigator saw a live feed showing employees "expediently signing and passing documents to one another." The inspector asked to be taken immediately to the area on screen but was "routed" to an incorrect area, preventing the inspector from seeing the papers that were being signed and passed along, the FDA said.

SPECIAL REPORT: The most significant FDA warning letters of 2019

In its September response to a Form 483 outlining the issues on site, Windlas admitted that its employees had violated its documentation procedures but "did not fully evaluate the scope of this deficiency," the FDA said. In addition, the company argued its camera placement procedure was incorrect, but the FDA pointed out the incorrect camera was approved within one week of the inspection taking place. 

In addition to those problems, investigators cited Windlas' inability to maintain complete records for its drug testing and procedures to keep manufactured meds within specifications before and after distribution. 

In its letter, dated March 10, the FDA required Windlas to perform an investigation of the extent of its record-keeping inaccuracies and complete action plans for the observations it cited within 15 days of receipt.

Suggested Articles

Bayer has withdrawn part of a proposed Roundup settlement after a judge questioned how it's handling potential future claims.

Consensus pegs cabotegravir peak sales at £750 million ($945 million), indicating it can grab about one-third of the current PrEP market.

The CEOs for COVID-19 vaccine partners Pfizer and BioNTech are sounding confident in their program as they gear up for phase 3.